Principal Financial Group Inc. Has $9.93 Million Holdings in ANI Pharmaceuticals, Inc. $ANIP

Principal Financial Group Inc. boosted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 19.1% in the first quarter, HoldingsChannel.com reports. The firm owned 129,148 shares of the specialty pharmaceutical company’s stock after buying an additional 20,679 shares during the period. Principal Financial Group Inc.’s holdings in ANI Pharmaceuticals were worth $9,931,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in ANI Pharmaceuticals by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after buying an additional 27,598 shares during the period. State Street Corp increased its stake in shares of ANI Pharmaceuticals by 2.2% in the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after buying an additional 15,496 shares during the period. UBS Group AG raised its position in shares of ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after acquiring an additional 185,172 shares during the last quarter. Tang Capital Management LLC lifted its stake in shares of ANI Pharmaceuticals by 51.6% in the fourth quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock worth $38,005,000 after acquiring an additional 163,937 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of ANI Pharmaceuticals by 4.2% in the fourth quarter. Geode Capital Management LLC now owns 477,272 shares of the specialty pharmaceutical company’s stock worth $37,682,000 after acquiring an additional 19,258 shares during the period. 76.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ANIP has been the topic of several analyst reports. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Canaccord Genuity Group initiated coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 16th. They issued a “hold” rating and a $91.00 price objective on the stock. Finally, Guggenheim reiterated a “buy” rating and set a $124.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $105.00.

Insider Transactions at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 500 shares of the stock in a transaction on Monday, July 13th. The stock was sold at an average price of $81.84, for a total value of $40,920.00. Following the transaction, the vice president directly owned 77,390 shares in the company, valued at $6,333,597.60. This trade represents a 0.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 3,313 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total transaction of $284,918.00. Following the sale, the chief financial officer owned 177,543 shares of the company’s stock, valued at $15,268,698. This trade represents a 1.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 85,179 shares of company stock valued at $6,722,596. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Trading Down 1.1%

NASDAQ ANIP opened at $77.65 on Friday. The business has a 50 day simple moving average of $81.26 and a 200 day simple moving average of $79.47. ANI Pharmaceuticals, Inc. has a one year low of $62.60 and a one year high of $99.50. The stock has a market capitalization of $1.77 billion, a P/E ratio of 19.66 and a beta of 0.43. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company’s revenue was up 20.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.